The case: A 47-year-old male undergoing chemotherapy for stage 3 locally advanced pancreatic cancer. He was cycling during hospital chemotherapy infusions (6 fortnightly cycles of FOLFIRINOX: 5-FU 2, 400 mg/m , over 48 h: irinotecan 180 mg/m , oxaliplatin 85 mg/m , no 5-FU bolus) ...
Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University, discusses important considerations for patients, caregivers, nurses and physicians when treatment with an immunotherapy begins.Recent Videos ...